Potassium bicarbonate 500mg capsules

BackgroundPatients with chronic kidney disease (CKD) often experience a decline in muscle mass and metabolic disturbances, which may increase the risk of cardiovascular events and all-cause mortality. Sodium bicarbonate, cholecalciferol, and protein supplementation are commonly used pharmacological and nutritional interventions; however, systematic evidence comparing their effects on muscle mass, metabolic status, and related outcomes in CKD patients remains lacking.MethodsWe systematically searched PubMed, Embase, Web of Science, and the Cochrane Library from inception to July 1, 2025, and included eligible comparative clinical studies. Conventional meta-analysis and network meta-analysis (NMA) were used to compare the three categories of interventions in outcomes such as muscle mass, muscle function, and serum metabolic parameters, and surface under the cumulative ranking curve (SUCRA) values were used to rank intervention effects.ResultsA total of 22 studies involving 2,879 patients were included, comprising 11 on sodium bicarbonate, 5 on cholecalciferol, and 6 on protein supplementation. Conventional meta-analysis indicated that sodium bicarbonate may be more effective in improving HCO₃- and potassium levels in the early stage and may have certain effects on eGFR and systolic blood pressure at 24 months. NMA results showed that cholecalciferol was advantageous in increasing muscle mass (SMD = 0.68, 95% CI = 0.09 to 1.27), sodium bicarbonate performed better in improving serum albumin (SMD = 0.50, 95% CI = 0.01 to 0.99), and protein supplementation ranked highest for reducing serum phosphorus (SUCRA = 64.9%) and the incidence of adverse events (SUCRA = 71.9%). However, no significant differences were observed among the three interventions in muscle mass or serum metabolic parameters.ConclusionSodium bicarbonate and cholecalciferol may have potential advantages in improving serum albumin and increasing muscle mass, respectively. While protein supplementation may offer some value in reducing serum phosphorus and the incidence of adverse events. Given the limited number of included studies, small sample sizes, and substantial heterogeneity in intervention protocols, these conclusions should be further validated in future large-scale, rigorously designed randomized controlled trials.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251126837, identifier PROSPERO (CRD420251126837).

Abstract licence: CC BY

IntroductionDistal renal tubular acidosis (dRTA) is a rare disorder characterized by normal anion gap metabolic acidosis and hypokalaemia. Physiological changes during pregnancy may aggravate acid-base imbalance and influence foetal outcomes.Case descriptionA 40-year-old pregnant woman at 24-25 weeks of gestation presented with recurrent hypokalaemia and lower limb weakness. Laboratory findings showed normal anion gap metabolic acidosis, consistent with dRTA. The patient was treated with oral potassium supplementation and intravenous sodium bicarbonate, resulting in clinical improvement. In the third trimester, intrauterine growth restriction was identified. Delivery at term resulted in a live neonate with low birth weight.A literature review was conducted according to Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines using PubMed, ScienceDirect, Wiley Online Library, SpringerLink, and ResearchGate for studies published between 2016 and 2026. Ten case reports met the inclusion criteria. Distal RTA was the most frequently reported subtype, accounting for 80% of cases. Most cases (70%) were first diagnosed during pregnancy. The most common treatment strategy was potassium supplementation combined with bicarbonate therapy (90%), administered either orally, intravenously, or as combination therapy. Adverse neonatal outcomes were reported in 50% of cases.ConclusionDistal RTA should be considered in pregnant patients presenting with recurrent hypokalaemia and muscle weakness. Early recognition and appropriate correction of electrolyte imbalance and metabolic acidosis are essential to optimize maternal and foetal condition. Further studies are needed to better define clinical characteristics and management strategies of renal tubular acidosis during pregnancy.Learning pointsVigilance is essential for rare distal renal tubular acidosis (dRTA)-pregnancy overlap As the leading form of RTA, (seen in 80% of reported cases), distal RTA (dRTA) frequently first appears during pregnancy (70% of instances), where it closely resembles routine hypokalaemic conditions. Clinicians should routinely check for anion-gap metabolic acidosis in pregnant women experiencing repeated muscle weakness, allowing timely treatment to avert severe maternal decline.Bicarbonate and potassium therapy boosts maternal-foetal success In this case, combined oral and intravenous replacement (effective in 90% of documented scenarios) quickly alleviated symptoms, yet the 50% chance of neonatal issues like intrauterine growth restriction or low birth weight underscores the approach's value for the foetus, providing internists with a reliable, safe strategy amid pregnancy's natural acid-base changes.Diagnostic pathway to reveal hidden dRTA dangers This experience arms internists with a straightforward algorithm (start with hypokalaemia evaluation, advance to acidosis testing) that cuts late-pregnancy risks, especially in settings with limited resources.

Abstract licence: CC BY-NC-ND

Monocarboxylate transporter 1 (MCT1) deficiency is an ultra-rare autosomal recessive metabolic disorder caused by pathogenic variants in the SLC16A1 gene, which encodes a proton-linked transporter of lactate, pyruvate, and ketone bodies. Few cases have been genetically confirmed worldwide, and diagnosis is often delayed due to nonspecific clinical features and the absence of characteristic metabolic markers. We report the case of a 5-year-old Egyptian boy with recurrent episodes of ketoacidosis and neurological symptoms, who was confirmed by whole-exome sequencing to have homozygous SLC16A1 pathogenic variants. Clinical data, biochemical findings, treatment course, and follow-up were documented in accordance with CARE guidelines. To contextualize this case, we conducted a systematic review of the literature following PRISMA 2020 guidelines, identifying genetically confirmed cases of MCT1 deficiency and summarizing clinical, genetic, and therapeutic insights. The patient presented with high anion gap metabolic acidosis (pH 6.8, bicarbonate 5.2 mmol/L) and normal glucose, lactate, and ammonia levels, consistent with impaired monocarboxylate transport. He developed severe rebound hypokalemia (serum potassium 1.7 mmol/L) during bicarbonate therapy, necessitating intensive correction. He recovered with supportive management, including careful fluid and electrolyte replacement. Our systematic review identified seven eligible studies, encompassing eight patients across six countries. Age of onset ranged from 2 months to 6 years, with clinical presentations including recurrent vomiting, lethargy, seizures, and metabolic crises. While outcomes varied, early recognition and supportive management were associated with more favorable neurodevelopmental trajectories. This study highlights the diagnostic and therapeutic challenges of MCT1 deficiency. The case illustrates not only the typical metabolic phenotype but also treatment-related complications such as hypokalemia. Findings from the systematic review emphasize the importance of genetic testing for early recognition, multidisciplinary management, and the need for greater clinical awareness of this emerging metabolic disorder. Expanding patient registries and investigating genotype-phenotype correlations are essential to improve outcomes in affected individuals.

Abstract licence: CC BY-ND